Becton, Dickinson and Company $BDX Shares Sold by AMI Asset Management Corp

AMI Asset Management Corp lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.4% during the first quarter, Holdings Channel.com reports. The firm owned 263,904 shares of the medical instruments supplier’s stock after selling 6,482 shares during the quarter. Becton, Dickinson and Company makes up 2.6% of AMI Asset Management Corp’s investment portfolio, making the stock its 16th largest position. AMI Asset Management Corp’s holdings in Becton, Dickinson and Company were worth $41,494,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of BDX. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $25,000. Steph & Co. lifted its position in shares of Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the last quarter. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $26,000. Prosperity Bancshares Inc bought a new stake in Becton, Dickinson and Company in the fourth quarter valued at $29,000. Finally, WPG Advisers LLC boosted its position in shares of Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 61 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.7%

BDX opened at $154.81 on Tuesday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The stock has a market capitalization of $42.66 billion, a PE ratio of 39.19, a PEG ratio of 11.04 and a beta of 0.22. The firm has a 50-day moving average price of $148.16 and a two-hundred day moving average price of $170.37.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is 106.33%.

Insiders Place Their Bets

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 5,188 shares of company stock valued at $765,120. Corporate insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of several research analyst reports. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Piper Sandler dropped their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus cut their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. TD Cowen cut their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. Finally, Barclays lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $181.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.